Patents by Inventor Nicholas Paul Camp

Nicholas Paul Camp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of the menin-MLL interaction
    Patent number: 11919901
    Abstract: The present disclosure is directed to inhibitors of Formula (0), or a stereoisomer thereof, or pharmaceutically acceptable salt thereof, of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction,
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: March 5, 2024
    Assignees: Syndax Pharmaceuticals, Inc., Vitae Pharmaceuticals, LLC
    Inventors: Gerard M. McGeehan, William H. Miller, Nicholas Paul Camp, Salvacion Cacatian, Santosh S. Kulkarni, Swapan Kumar Samanta, Virsinha Venkat Reddy
  • INHIBITORS OF THE MENIN-MLL INTERACTION
    Publication number: 20230021684
    Abstract: The present disclosure is directed to inhibitors of Formula (0), or a stereoisomer thereof, or pharmaceutically acceptable salt thereof, of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: May 13, 2022
    Publication date: January 26, 2023
    Inventors: Gerard M. MCGEEHAN, William H. MILLER, Nicholas Paul CAMP, Salvacion CACATIAN, Santosh S. KULKARNI, Swapan Kumar SAMANTA, Virsinha Venkat REDDY
  • Substituted [1,2,4]triazolo[4,3-a]pyrazines as phosphodiesterase inhibitors
    Patent number: 11453673
    Abstract: The present invention provides a compound of Formula I: wherein R1 is methyl, ethyl or cyclopropyl; R2 is hydrogen, methyl, or ethyl; R3 is methyl or AA; and R4 is C2-C4 alkyl, BB; or a pharmaceutically acceptable salt thereof; for use as a PDE1 inhibitor.
    Type: Grant
    Filed: January 13, 2019
    Date of Patent: September 27, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: Nicholas Paul Camp, Chafiq Hamdouchi, Jayana Pankaj Lineswala, John Richard Morphy, Qing Shi
  • [1,2,4]TRIAZOLO[4,3-A]PYRAZIN-8-ONE DERIVATIVES
    Publication number: 20200399277
    Abstract: The present invention provides a compound of Formula I: wherein R1 is methyl, ethyl or cyclopropyl; R2 is hydrogen, methyl, or ethyl; R3 is methyl or AA; and R4 is C2-C4 alkyl, BB; or a pharmaceutically acceptable salt thereof; for use as a PDE1 inhibitor.
    Type: Application
    Filed: January 13, 2019
    Publication date: December 24, 2020
    Inventors: Nicholas Paul CAMP, Chafiq HAMDOUCHI, Jayana Pankaj LINESWALA, John Richard MORPHY, Qing SHI
  • DGAT2 inhibitors
    Patent number: 9073901
    Abstract: The present invention provides compounds of the Formula below: where R is H or —CH3; methods of treating patients for hypertriglyceridemia and cardiovascular disease including dyslipidemia and atherosclerosis, and processes for preparing the compounds.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: July 7, 2015
    Assignee: Eli Lilly and Company
    Inventors: Manisha Naik, Nicholas Paul Camp
  • NOVEL DGAT2 INHIBITORS
    Publication number: 20150148358
    Abstract: The present invention provides compounds of the Formula below: where R is H or —CH3; methods of treating patients for hypertriglyceridemia and cardiovascular disease including dyslipidemia and atherosclerosis, and processes for preparing the compounds.
    Type: Application
    Filed: November 19, 2014
    Publication date: May 28, 2015
    Applicant: Eli Lilly and Company
    Inventors: Manisha NAIK, Nicholas Paul CAMP
  • Serine protease inhibitors
    Patent number: 7351822
    Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: April 1, 2008
    Assignee: Eli Lilly and Company
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson, Peter Robert Guzzo, Michael John Mayer
  • Isochroman compounds for treatment of CNS disorders
    Patent number: 7335660
    Abstract: This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, p and n have the values defined in claim 1, their preparation and use as pharmaceuticals for the treatment of central nervous system disorders, such as depression, bipolar disorder, and anxiety.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: February 26, 2008
    Assignee: Eli Lilly and Company
    Inventors: Javier Agejas-Chicharro, Graham Henry Timms, Andrew Caerwyn Williams, Nicholas Paul Camp, Jeremy Gilmore, Ana Belen Bueno Melendo, Carlos Lamas-Peteira
  • Serine protease inhibitors
    Patent number: 7053078
    Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: May 30, 2006
    Assignee: Eli Lilly and Company
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson
  • Serine protease inhibitors
    Patent number: 6946467
    Abstract: The compound 1-(indole-6-carbonyl-D-phenylglycinyl)-4-(1-methylpiperidin-4-yl)piperazine and physiologically-tolerable salts thereof are factor Xa inhibitors useful for the treatment of thrombotic disorders.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: September 20, 2005
    Assignee: Eli Lilly and Company
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson, Peter Robert Guzzo, Michael John Mayer
  • Serine protease inhibitors
    Patent number: 6936611
    Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.
    Type: Grant
    Filed: January 12, 2004
    Date of Patent: August 30, 2005
    Assignee: Eli Lilly and Company
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson, Peter Robert Guzzo, Michael John Mayer
  • Serine protease inhibitors
    Patent number: 6900196
    Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.
    Type: Grant
    Filed: July 6, 2004
    Date of Patent: May 31, 2005
    Assignee: Eli Lilly and Company
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson
  • Serine protease inhibitors
    Patent number: 6878725
    Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: April 12, 2005
    Assignee: Eli Lilly and Company
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson
  • Serine protease inhibitors
    Patent number: 6855715
    Abstract: Compounds of formula (I) where R2, each X, L, Y, Cy, Lp, D and n are as defined in the specification, are serine protease inhibitors useful as antithrombotic agents.
    Type: Grant
    Filed: June 13, 2000
    Date of Patent: February 15, 2005
    Assignee: Eli Lilly and Company
    Inventors: John Walter Liebeschuetz, Amanda Jane Lyons, Christopher William Murray, Andrew David Rimmer, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, Phillip John Morgan, Simon James Richards, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley
  • Serine protease inhibitors
    Publication number: 20040259868
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: July 6, 2004
    Publication date: December 23, 2004
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson
  • Serine protease inhibitors
    Publication number: 20040242656
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: June 28, 2004
    Publication date: December 2, 2004
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson
  • Serine protease inhibitors
    Publication number: 20040176363
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: March 18, 2004
    Publication date: September 9, 2004
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson, Peter Robert Guzzo, Michael John Mayer
  • Serine protease inhibitors
    Patent number: 6784182
    Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, factor Xa and are useful in the treatment of cardiovascular disorders.
    Type: Grant
    Filed: February 4, 2002
    Date of Patent: August 31, 2004
    Assignee: Eli Lilly and Company
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson
  • Serine protease inhibitors
    Publication number: 20040142963
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: January 12, 2004
    Publication date: July 22, 2004
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson, Peter Robert Guzzo, Michael John Mayer
  • Pharmaceutical compounds
    Publication number: 20040122001
    Abstract: This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, m and n have the values defined in claim 1, their preparation and use as pharmaceuticals.
    Type: Application
    Filed: January 16, 2004
    Publication date: June 24, 2004
    Inventors: Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Nicholas Paul Camp, Jeremy Gilmore, Alma Maria Jimenez-Aguado, Carlos Lamas-Peteira, Alicia Marcos-Llorente, Michael Philip Mazanetz, Carlos Montero Salgado, Graham Henry Timms, Andrew Caerwyn Williams